At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 86 enrolled
Drug / intervention
Tafenoquine Oral Tablet +1 moredrug
Likely dose
Tafenoquine Oral Tablet 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease
In Brief
A Phase 2 clinical trial evaluating Tafenoquine Oral Tablet and Placebo for COVID 19 Disease. Completed, enrolled 86 participants across 10 sites.
Detailed Summary
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID 19 Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartFeb 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedAug 31, 2020
Enrollment StartFeb 19, 2021
Primary CompletionJun 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.8 years ago
Interventions
Tafenoquine Oral Tabletdrug
Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.
Placebodrug
Patients will be randomized and will receive and self-administer 200 mg Tafenoquine or matching placebo on Days 1, 2, 3, and 10.